Yosemite
Status
ACTIVE
Global HQ
San Francisco, United States
Countries of investment
- United States
Investment stages
- Seed
- Series A
- Series B
Industries
- Biotechnology
- Life Sciences
- Precision Medicine
- Diagnostics
- Digital Health
- Health Tech
- Biologics
- AI
- Pharma
About
Yosemite is a San Francisco-based, cancer-focused venture firm founded by Reed Jobs, spun out of Laurene Powell Jobs's Emerson Collective in 2023 and managing more than $1B including holdings carried over from Emerson. Its first fund closed at $263M in 2024 after a $200M first close in 2023. In November 2026 it held the final close of its oversubscribed second fund at $350M, up from a $200M first close in January 2026, with limited partners including Amgen, AbbVie, MIT, Memorial Sloan Kettering and John Doerr. Fund II plans to back about 25 companies, with several incubations underway including in radiopharmaceuticals, alongside philanthropic grants to academic researchers that have exceeded $18M since 2023, partly through a partnership with the American Cancer Society. Portfolio companies include Chai Discovery, Tune Therapeutics, Azalea Therapeutics and Teal Health.
Yosemite is a San Francisco-based, cancer-focused venture firm founded by Reed Jobs, spun out of Laurene Powell Jobs's Emerson Collective in 2023 and managing more than $1B including holdings carried over from Emerson. Its first fund closed at $263M in 2024 after a $200M first close in 2023. In November 2026 it held the final close of its oversubscribed second fund at $350M, up from a $200M first close in January 2026, with limited partners including Amgen, AbbVie, MIT, Memorial Sloan Kettering and John Doerr. Fund II plans to back about 25 companies, with several incubations underway including in radiopharmaceuticals, alongside philanthropic grants to academic researchers that have exceeded $18M since 2023, partly through a partnership with the American Cancer Society. Portfolio companies include Chai Discovery, Tune Therapeutics, Azalea Therapeutics and Teal Health.
Investment Thesis
Yosemite invests exclusively in oncology, backing early-stage therapeutics, diagnostics, tools and digital health companies with the stated goal of making cancer non-lethal within our lifetime. It focuses mainly on pre-IND and early clinical companies, often first-in-class, and helps create about a third of its venture companies itself, many of them emerging from academic labs it has funded. Its edge is a hybrid model that pairs the venture fund with a donor-advised philanthropic vehicle giving no-strings research grants to academic scientists, which gives it early access to investable science.
Manager's Experience
Reed Jobs joined Emerson Collective at 24 in 2015 to lead its oncology-focused health strategy and became its Managing Director of Health, supporting hundreds of researchers and investing in dozens of therapeutic, diagnostic and digital health companies before spinning the team out as Yosemite in 2023. Daniel McHugh, head of the investment team, came from the same Emerson health team and served as interim CEO of portfolio company Tune Therapeutics in 2024. Matt Bettonville leads digital health and care delivery investments after working on Emerson's Count Me In partnership with the Broad Institute and as a software engineer at Apple.
Team
Reed Jobs - Founder and Managing Partner
Daniel McHugh - Head of Investment Team
Matt Bettonville - Investor
Beverly Lu - Investor
Portfolio
Chai Discovery
Tune Therapeutics
Azalea Therapeutics
Teal Health
Quarry Therapeutics
HistoSonics
Sage Care
Turquoise Health
Atropos Health
1063 Therapeutics